美康生物(300439) - 2024 Q3 - 季度财报

Financial Performance - Revenue for Q3 2024 was CNY 457,584,796.66, a decrease of 7.34% year-over-year[3] - Net profit attributable to shareholders was CNY 45,900,372.79, down 16.68% compared to the same period last year[3] - Basic earnings per share decreased by 16.90% to CNY 0.1195[3] - The company reported a revenue of 1,406.71 million RMB for the first nine months of 2024, a decrease of 4.35% year-on-year[11] - The net profit attributable to shareholders for the same period was 224.36 million RMB, down 2.43% year-on-year, while the net profit excluding non-recurring items increased by 7.16% to 193.34 million RMB[11] - The net profit for Q3 2024 was approximately ¥223.33 million, a slight decrease from ¥223.64 million in Q3 2023, representing a decline of 0.14%[15] - Total revenue from operating activities decreased to ¥1.54 billion in Q3 2024, down from ¥1.78 billion in Q3 2023, reflecting a decline of 13.5%[17] - The company's operating profit for Q3 2024 was ¥250.21 million, compared to ¥259.65 million in Q3 2023, a decrease of 3.6%[15] - The total comprehensive income for Q3 2024 was approximately ¥219.08 million, compared to ¥222.49 million in Q3 2023, a decrease of 1.9%[16] Assets and Liabilities - Total assets increased by 2.12% to CNY 3,563,198,864.29 compared to the end of the previous year[3] - The company reported a trading financial asset balance of 255.38 million RMB as of September 30, 2024, compared to 6 million RMB at the beginning of the period[12] - Non-current assets totaled CNY 1,765,123,689.86, up from CNY 1,590,020,395.90, indicating an increase of approximately 11%[13] - Total liabilities decreased to CNY 682,794,918.22 from CNY 782,493,044.11, a reduction of about 12.7%[14] - The company's equity attributable to shareholders rose to CNY 2,888,835,756.70 from CNY 2,714,933,902.95, reflecting an increase of approximately 6.4%[14] Cash Flow - Cash flow from operating activities decreased by 70.83% to CNY 109,039,623.15[3] - The company's cash flow from investing activities was negative CNY 393,618,233.08, reflecting increased purchases of financial products[7] - The net cash flow from operating activities was 109,039,623.15, a decrease of 70.2% compared to 373,776,026.11 in the previous year[18] - The total cash inflow from investment activities was 479,909,809.39, up 60.8% from 298,365,481.51 in the same period last year[18] - The net cash flow from investment activities was -393,618,233.08, worsening from -86,074,129.29 year-over-year[18] - The cash outflow from financing activities totaled 109,945,542.21, a decrease of 48.7% compared to 214,280,180.91 in the previous year[18] - The net cash flow from financing activities was -78,095,542.21, improving from -164,280,180.91 year-over-year[18] - The total cash and cash equivalents decreased by 361,519,163.82, contrasting with an increase of 123,204,663.11 in the previous year[18] Shareholder Information - The total number of common shareholders at the end of the reporting period was 28,253[8] - The top ten shareholders held a combined 28.36% of the company's shares, with the largest shareholder holding 108,897,635 shares[9] - The company had 81,673,226 shares under lock-up for management, with a release plan allowing for a maximum of 25% to be sold annually during their tenure[10] Government and Investment - The company received government subsidies amounting to CNY 16,854,995.32, a decrease of 35.54% from the previous year[7] - The company’s investment income rose by 38.43% to CNY 14,474,621.09 due to gains from long-term equity investments[7] - The company recorded investment income of ¥14.47 million, an increase from ¥10.46 million in Q3 2023, representing a growth of 38.7%[15] Research and Development - The company aims to enhance its market share in self-produced instruments and reagents to offset the impact of price reductions from centralized procurement[11] - The company plans to accelerate the development of new products such as mass spectrometry and precision blood lipid testing to create new growth points[11] - Research and development expenses were ¥114.75 million, slightly down from ¥118.63 million in the previous year, indicating a decrease of 3.2%[15] Tax and Expenses - The company reported a tax expense of ¥31.65 million for Q3 2024, down from ¥40.07 million in Q3 2023, a reduction of 21.1%[15] - Sales expenses for Q3 2024 were ¥189.44 million, a decrease from ¥196.05 million in the same period last year, representing a decline of 3.1%[15] - The cash paid for taxes was 88,820,205.00, down from 111,280,013.38 in the previous year, indicating a 20.2% decrease[18] Audit Information - The company did not undergo an audit for the third quarter report[19]